The Tariff Problem Is Real. Here’s How to Play It.
Every small-cap investor is asking the same question in May 2026: which companies actually survive the tariff cycle without getting clipped? The answer isn’t complicated. You find companies where revenue stays inside US borders — no Chinese supply chain, no export dependency, no “we’re monitoring the situation” language in their 10-K.
I went through the marginofalpha paper portfolio (17 positions, started February 2026) and pulled out five holdings that share one trait: zero meaningful China revenue exposure. Then I added the numbers, the bear cases, and the price levels where each one becomes interesting vs. expensive.
As of May 4, these five positions collectively returned +22.7% vs. the portfolio’s overall +8.8%.
1. UAMY — United States Antimony ($12.15, +22% since entry)
We’ve covered UAMY before, but the thesis keeps compounding. United States Antimony is the only publicly traded domestic antimony producer. Antimony is a critical mineral used in defense munitions, flame retardants, and lead-acid batteries.
China controls roughly 48% of global antimony supply and restricted exports in late 2024. That restriction didn’t ease — it tightened. UAMY’s revenue surged 163% to $39.3M in their latest reported period, driven by higher prices and new contracts. The company carries near-zero debt (D/E ratio of 0.17) and has a $4.6B tungsten resource sitting in Montana that the market hasn’t priced in yet.
2026 revenue guidance sits around $125M. At a $1.4B market cap, that’s roughly 11x forward revenue — not cheap, but reasonable for a company growing 163% with a domestic monopoly narrative and defense tailwinds.
Bear case: Antimony prices could normalize if China reverses export restrictions. The stock has already run from $4 to $12 in six months — late buyers are paying for growth that needs to materialize quarter after quarter. At $12, you’re trusting management to execute on expansion in Montana, Alaska, and Canada simultaneously.
Where it gets interesting: Below $10. Above $15, you need to see that $125M guidance confirmed in actual filings.
2. CDNL — Cardinal Infrastructure Group ($54.69, +34% since entry)
Cardinal Infrastructure does domestic engineering and infrastructure work. Roads, bridges, water systems. Boring? Yes. Tariff-proof? Absolutely.
The company posted 71.7% revenue growth and was added to the Russell Small Cap Value Index in March 2026. At a $626M market cap with a 26.9x P/E, CDNL isn’t a value play — it’s a growth play hiding in an unglamorous sector. Pure domestic revenue means zero tariff exposure in any trade scenario.
We wrote up CDNL when it was $40. The stock has since climbed 34%, validating the domestic infrastructure thesis. The Russell inclusion brought institutional buyers, and the 25.6% four-week price momentum at time of entry confirmed real demand.
Bear case: Government infrastructure spending depends on political cycles. A budget crunch or administration change could slow contract awards. At $54.69, you’re paying 26.9x earnings for a construction company — that works if growth sustains, but it leaves no margin for a slowdown.
Where it gets interesting: On a pullback to the mid-$40s. Current price already reflects most of the good news.
3. HDSN — Hudson Technologies ($6.25, flat since entry)
Hudson Technologies reclaims and recycles refrigerant gases. It’s niche, regulated, and structurally protected by the AIM Act — a federal law phasing down HFC refrigerants. As supply shrinks legally, HDSN’s recycled inventory becomes more valuable.
Revenue grew 28.2% in the latest period. The P/E is 16.8x — one of the cheapest in our entire portfolio. At a ~$260M market cap, this is a micro-cap that institutions haven’t discovered yet.
The thesis is mechanical: the AIM Act forces HFC phase-down, supply tightens, recycled refrigerant prices rise, HDSN makes more money per unit. No China exposure. No tariff risk. The catalyst is federal regulation, not trade policy.
Bear case: Refrigerant recycling isn’t a growth business — it’s a margin business. Revenue growth of 28% is strong, but if the AIM Act timeline gets delayed (it’s happened before), the thesis stalls. The stock has gone nowhere in the 39 days we’ve held it, suggesting the market isn’t buying the re-rating story yet.
Where it gets interesting: Right here, at $6.25. The risk/reward at 16.8x earnings with a regulatory tailwind is solid. Just don’t expect fireworks.
4. EVLV — Evolv Technologies ($7.29, +38% since entry)
Evolv makes AI-powered weapons screening for stadiums, schools, and corporate buildings. Their scanners replace metal detectors with sensor fusion software that can distinguish a gun from a laptop.
The company just crossed EBITDA-positive for the first time ($5.1M in Q3). Revenue grew 57% year-over-year to $42.9M, beating estimates by 27%. ARR hit $117.2M, up 25%. They serve 1,000+ enterprise customers, all domestic.
Analyst consensus target: $9.88. Current price: $7.29. That’s 35% implied upside, and the company is hitting operational milestones faster than expected.
Bear case: Evolv went public via SPAC and the hangover hasn’t fully cleared. Short interest remains elevated. The security screening market is competitive — traditional metal detectors cost a fraction of what Evolv charges. If enterprise budgets tighten, discretionary security upgrades get cut first. The company also has warrants and legacy SPAC dilution overhang.
Where it gets interesting: Under $7. At $7.29, the risk/reward is fair but not screaming cheap. A pullback to the $6 range would be compelling given the operational trajectory.
5. CPRX — Catalyst Pharmaceuticals ($28.74, +16% since entry)
Catalyst Pharmaceuticals sells one approved drug — Firdapse, for Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disease. The company has zero net debt, 15.3% revenue growth, and trades at 14.5x forward earnings.
Forbes ranked CPRX #11 on their 2026 America’s Most Successful Small-Cap Companies list. Q4 earnings beat by $0.37 on EPS (61% above estimates). The royalty stream from Firdapse creates recurring cash flow that doesn’t depend on pipeline bets.
This is a pharma company with approved product revenue, positive earnings, and no debt. That profile is rare in small-cap biotech, where most names are burning cash hoping for FDA approval.
Bear case: One-product dependency. If Firdapse faces generic competition or a safety issue, there’s nothing to fall back on. Revenue growth of 15% is steady but not exciting. The stock has drifted between $24-$30 for months — the market sees it as fairly valued, not misunderstood.
Where it gets interesting: Below $25. At $28.74, you’re paying fair value for a steady compounder. Wait for a dip.
Why “Domestic-Only” Matters More Than You Think
The 2026 tariff regime isn’t a one-quarter event. Companies with China exposure face ongoing uncertainty — will tariffs go up, down, or stay? That unpredictability kills valuation multiples. Markets hate uncertainty more than they hate bad news.
Companies with 100% domestic revenue avoid that entire conversation. Their cost structures are predictable. Their customer base isn’t affected by trade retaliation. Their supply chains don’t get rerouted mid-quarter.
This doesn’t make them automatically good investments — CDNL at 27x earnings for a construction company is a stretch, and HDSN has yet to prove it can re-rate. But it does remove one major variable from the analysis. In a tariff-driven market, that’s worth something.
The Portfolio Reality Check
Our paper portfolio has 17 positions. Five of them are profiled above because they fit the “tariff-proof” criteria. The other 12 have varying degrees of international or supply chain exposure — and several of those are underwater (OFRM -26%, YEXT -27%, ABX -7%).
That’s not proof that domestic-only is the winning strategy. SERV, our autonomous delivery play, is also down 4.5% despite being a US-focused company. But the pattern is clear: in 2026’s tariff environment, domestic revenue has been a tailwind, and China exposure has been a headwind.
If the trade war eases, this trade reverses hard. These five stocks would likely underperform international-facing peers that are currently depressed. That’s the bet: you’re trading upside optionality for downside protection.
Bottom Line
If you want small-cap exposure without tariff anxiety, these five names are a starting point — not a shopping list. The best entries are on pullbacks, not after 30%+ runs. HDSN and CPRX offer the best value entry points right now. UAMY and CDNL have already priced in significant growth. EVLV sits in the middle.
As always, size positions based on your risk tolerance and time horizon. Small caps are volatile even without trade wars.
This article is for informational purposes only and does not constitute financial advice. Always do your own research and consider consulting with a financial advisor before making investment decisions. The author holds paper portfolio positions in all five stocks discussed.